The Selective Phosphodiesterase 4 Inhibitor Roflumilast and Phosphodiesterase 3/4 Inhibitor Pumafentrine Reduce Clinical Score and TNF Expression in Experimental Colitis in Mice-Reference-Cited by-同舟云学术

The Selective Phosphodiesterase 4 Inhibitor Roflumilast and Phosphodiesterase 3/4 Inhibitor Pumafentrine Reduce Clinical Score and TNF Expression in Experimental Colitis in Mice

Published:2013-02-28 Issue:2 Volume:8 Page:e56867
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Rieder Florian,Siegmund Britta,Bundschuh Daniela S.,Lehr Hans-Anton,Endres Stefan,Eigler Andreas

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference40 articles.

1. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease;SH Murch;Gut,1993

2. Inflammatory bowel disease;DK Podolsky;N Engl J Med,2002

3. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease;P Rutgeerts;Gastroenterology,1999

4. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety;WJ Sandborn;Inflamm Bowel Dis,1999

5. Infliximab for induction and maintenance therapy for ulcerative colitis;P Rutgeerts;N Engl J Med,2005

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of novel N2-indazole derivatives as phosphodiesterase 4 inhibitors for the treatment of inflammatory bowel disease;European Journal of Medicinal Chemistry;2024-11

2. Cyclic adenosine 3’, 5’-monophosphate (cAMP) signaling is a crucial therapeutic target for ulcerative colitis;Life Sciences;2024-09

3. Beyond the heart - Exploring the therapeutic potential of PDE3 inhibitors;Journal of Research in Pharmacy;2023

4. Rectal roflumilast improves trinitrobenzenesulfonic acid-induced chronic colitis in rats;Brazilian Journal of Medical and Biological Research;2022

5. TGF-β activity restoration and phosphodiesterase 4 inhibition as therapeutic options for inflammatory bowel diseases;Pharmacological Research;2020-05